CANC vs MDEV: Holdings Overlap & Returns

Over the year to Nov 13, 2026, CANC returned +25.2% to MDEV's +8.8%; 0% of their weight is in the same names.

Return gap
+16.4 pts1 year to Nov 13, 2026: CANC ahead, total return
Fee gap
0.05 ptsA year: CANC 0.75%, MDEV 0.70%, per filings dated Jun 29, 2026 and Jul 29, 2026
Overlap
0%Share of the two books held in common, holdings dated Nov 12, 2026
Net flow
–Needs daily flows for both funds
The answerOne drawing that carries it.

Compare two other funds

The evidenceWhy, in charts and cards.
CANC and MDEV · 1 year

Growth of 100

CANC +25.2%MDEV +8.8%
Growth of 100 in CANC and MDEV over 1 year, Nov 13, 2025 to Nov 13, 2026, with distributions reinvested. CANC ends at 125.2 (+25.2%), MDEV at 108.8 (+8.8%).

CANC +25.2%, MDEV +8.8%: CANC +16.4 pts ahead, 1 year, Nov 13, 2025 to Nov 13, 2026.

Share

Use this comparison

Alert

CANC and MDEV flows, by email on Sundays.

One-click unsubscribe. See Privacy.

Hypothetical · drag the order size

Cost to trade

Hypothetical. A $10,000 order in MDEV costs about $9.50 one way and $19.00 in and out, at a median spread of 0.19%. The 0.19% spread is MDEV’s 30-day median, from First Trust (fund page).

Hypothetical · drag to set

Fees over time

Hypothetical. $10,000 in CANC for 10 years at 0.75% a year costs about $1,228 in fees and lost growth; MDEV at 0.70% would cost $1,148. Assumes 6% a year before fees, a sample rate, not a forecast.

How each fund moved

CANC · 1 year to Nov 13, 202677% of its weight is outside the S&P 500
77% of its weight is outside the S&P 50023% of CANC's weight is in S&P 500 companies and 77% is outside the index. Holdings as of Nov 12, 2026.23%77%in the S&P 500of its weight outside the S&P 500active share 96% · top ten 46% of the fund · 55 holdings as published by its issuer for Nov 12, 2026 · Nasdaq-100: 3% in77% of its weight is outside the S&P 50023% of CANC's weight is in S&P 500 companies and 77% is outside the index. Holdings as of Nov 12, 2026.23%77%inoutside the S&P 500active share 96% · Nasdaq-100: 3% in

23% of CANC's weight is in S&P 500 companies and 77% is outside the index. Holdings as of Nov 12, 2026.

MDEV · 1 year to Nov 13, 202652% of its weight is outside the S&P 500
52% of its weight is outside the S&P 50048% of MDEV's weight is in S&P 500 companies and 52% is outside the index. Holdings as of Nov 12, 2026.48%52%of its weight in S&P 500 companiesof its weight outside the S&P 500active share 98% · top ten 23% of the fund · 50 holdings as published by its issuer for Nov 12, 2026 · Nasdaq-100: 6% in52% of its weight is outside the S&P 50048% of MDEV's weight is in S&P 500 companies and 52% is outside the index. Holdings as of Nov 12, 2026.48%52%in the S&P 500outside the S&P 500active share 98% · Nasdaq-100: 6% in

48% of MDEV's weight is in S&P 500 companies and 52% is outside the index. Holdings as of Nov 12, 2026.

Key numbers

CANC in the S&P 500
22.8%
MDEV in the S&P 500
47.8%
CANC total return, 1 year
+25.2%
MDEV total return, 1 year
+8.8%

MDEV costs 0.05 points a year less; their one-year returns differ by 16.4 points; CANC is far larger, $210m against $3.4m.

Pair scorecard

Open the table

Points (pts) are percentage points.

Total return, 1 year+25.2%+8.8%
Below its all-time high9.2%, high on Aug 25, 202619.1%, high on Sep 7, 2021
What it tracksTherapeutics and medical devicesTherapeutics and medical devices
Expense ratio0.75%0.70%
Net assets, as of Nov 12, 2026$210m$3.4m
Holdings in common0%

The numbers behind it

Net assets on Nov 12, 2026: $210m for Tema Oncology ETF and $3.4m for First Trust Indxx Medical Devices ETF.

Holdings in common uses holdings dated Nov 12, 2026.

What they share

By the books each fund has filed, CANC and MDEV hold 0% of their money in the same securities at the same weight. Holdings dated Nov 12, 2026.

0half (50%)100%

half

0% in common

Only in CANC

Show all 8 holdings
GENMAB A/S5.82%
ELI LILLY & CO5.62%
REVOLUTION MEDICINES INC5.34%
MERCK & CO INC5.03%
BEONE MEDICINES LTD4.34%
COGENT BIOSCIENCES INC4.31%
NOVARTIS AG4.19%
ABBVIE INC3.88%

Only in MDEV

Show all 8 holdings
GE HealthCare Technologies Inc.2.35%
Edwards Lifesciences Corporation2.34%
Koninklijke Philips N.V.2.33%
Teleflex Incorporated2.31%
Straumann Holding AG (Registered)2.24%
Steris Plc2.23%
LivaNova Plc2.22%
Becton, Dickinson and Company2.21%

Side by side

Open the table
FundTema Oncology ETF · Holds 55 stocks in therapeutics and medical devices, 23% of its weight in S&P 500 companiesFirst Trust Indxx Medical Devices ETF · Holds 50 stocks in therapeutics and medical devices, 48% of its weight in S&P 500 companies
IssuerTemaFirst Trust
ThemeTherapeutics and medical devicesTherapeutics and medical devices
In the S&P 50022.8%47.8%
Active share vs the S&P 50095.7%98.0%
In the Nasdaq-1003.1%6.1%
Holdings5550
Top ten, share of the fund45.5%22.6%
Expense ratio0.75%0.70%
Fee for the differing part0.78%0.71%
Total return, 1 year+25.2%+8.8%
vs its benchmarknot measurednot measured
Below its high−9.2%−19.1%
Net assets, as of Nov 12, 2026$210m$3.4m

As of Nov 13, 2026. Source: ETFIQ.

Window by window

Open the table
3 months−3.8%+5.5%
6 months+10.7%+26.9%
1 year+25.2%+8.8%
3 years+85.9%+27.4%
Since launch (Not the same days: CANC Aug 2023 · MDEV Jun 2021)+69.4%−10.2%

About CANC

By weight, 23% of CANC's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 96%. The top ten holdings are 46% of the fund across 55 positions, as published by its issuer for Nov 12, 2026.

More

Over the year to Nov 13, 2026 the fund returned +25.2% with distributions reinvested. It sits 9.2% below its all-time high of Aug 25, 2026.

About MDEV

By weight, 48% of MDEV's portfolio is stocks that are also in the S&P 500; its active share against the S&P 500 is 98%. The top ten holdings are 23% of the fund across 50 positions, as published by its issuer for Nov 12, 2026.

More

Over the year to Nov 13, 2026 the fund returned +8.8% with distributions reinvested. It sits 19.1% below its all-time high of Sep 7, 2021.

0% of the two portfolios are the same securities at the same weight.

Questions people ask

Do CANC and MDEV hold the same stocks?

By their latest filings, 0% of their books are the same securities at the same weight. Overlap is the sum of the smaller weight of every security they share.

Which is more different from the S&P 500, CANC or MDEV?

CANC has 23% of its weight in S&P 500 names and MDEV has 48%, so MDEV differs more from the index.

Which is cheaper, CANC or MDEV?

CANC charges 0.75% a year and MDEV charges 0.70%, so MDEV is cheaper. Fees come from each fund's prospectus.

Other comparisons

Sources

More

Links are sources, not endorsements. A comparison is not a recommendation.

Copy and cite

Cite this pageCitation, APA and Markdown

ETFIQ, CANC against MDEV, data as of Nov 13, 2026. https://etfiq.com/compare/themes/canc-vs-mdev

Open data

Free to use with attribution for data ETFIQ computes; issuer data stays under its owner's terms.